The Special Pathogens Research Network: Enabling Research Readiness.

External link

Original Article

The 2013-2016 epidemic of Ebola virus disease (EVD) that originated in West Africa underscored many of the challenges to conducting clinical research during an ongoing infectious disease epidemic, both in the most affected countries of Guinea, Liberia, and Sierra Leone, as well as in the United States and Europe, where a total of 27 patients with EVD received care in biocontainment units. The Special Pathogens Research Network (SPRN) was established in the United States in November 2016 to provide an organizational structure to leverage the expertise of the 10 Regional Ebola and Other Special Pathogen Treatment Centers (RESPTCs); it was intended to develop and support infrastructure to improve readiness to conduct clinical research in the United States. The network enables the rapid activation and coordination of clinical research in the event of an epidemic and facilitates opportunities for multicenter research when the RESPTCs are actively caring for patients requiring a biocontainment unit. Here we provide an overview of opportunities identified in the clinical research infrastructure during the West Africa EVD epidemic and the SPRN activities to meet the ongoing challenges in the context of Ebola virus and other special pathogens.


Back to Top

People

Amany Qaddour

Dr. Qaddour is the director of the 501(c)(3) humanitarian NGO Syria Relief &...

Read More

Frances Stead Sellers

Frances Stead Sellers is an associate editor of The Washington Post. She has...

Read More

Takeru (Tak) Igusa

Takeru (Tak) Igusa is a professor of civil and systems engineering and a leading...

Read More

Meighan Mary

Ms. Mary is an Assistant Scientist in the International Health Department of the...

Read More

Natalya Kostandova

Dr. Natalya Kostandova is an epidemiologist, with training focused on infectious...

Read More

Events

S
M
T
W
T
F
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·
·
·